# Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

> **NCT05212597** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 100 (estimated)

## Conditions studied

- Aortic Valve Insufficiency

## Interventions

- **DRUG:** Sacubitril-valsartan
- **DRUG:** Amlodipine-losartan

## Key facts

- **NCT ID:** NCT05212597
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-12
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212597, "Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05212597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*